Name: MMAE (Monomethyl auristatin E)
Brand: Selleck Chemicals
SKU: S7721
Rating: 5 (8 reviews)

Vai a

Controllo Qualità (Quality Control)

Lotto: Purezza: 99.99%

99.99

Target correlati	Akt Wnt/beta-catenin PKC HSP ROCK Microtubule Associated Integrin Bcr-Abl Actin FAK
Altro ADC Cytotoxin Inibitori	Triptolide SN-38 Luteolin (+)-Bicuculline Rutin Artemisinin BHQ Pinocembrin Luteoloside Lappaconite HBr

Coltura cellulare, trattamento e concentrazione di lavoro
(Cell Culture, Treatment & Working Concentration)

Linee cellulari	Tipo di saggio	Concentrazione	Tempo di incubazione	Descrizione dell'attività	PMID
KB	Antiproliferative assay		4 days	Antiproliferative activity against human KB cells after 4 days by XTT assay, IC50=0.00019μM	23845743
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	23845743
A549	Antiproliferative assay		4 days	Antiproliferative activity against human A549 cells after 4 days by XTT assay, IC50=0.00059μM	23845743
non-small cell lung cancer cells	Cytotoxicity assay	0.5 to 1 nM	4 days	Cytotoxicity against human non-small cell lung cancer cells at 0.5 to 1 nM after 4 days by XTT assay	23845743
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	25431858
MDA-MB-361	Cytotoxicity assay			Cytotoxicity against human MDA-MB-361 cells assessed as cell viability incubated fore 4 days by MTS assay, GI50=0.00049μM	25431858
NCI-N87	Cytotoxicity assay			Cytotoxicity against human NCI-N87 cells assessed as cell viability incubated fore 4 days by MTS assay, GI50=0.00054μM	25431858
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	28211277
DU145	Growth inhibition assay		48 hrs	Growth inhibition of human DU145 cells incubated for 48 hrs by MTT assay, GI50=0.000418μM	28211277
SF268	Growth inhibition assay		48 hrs	Growth inhibition of human SF268 cells incubated for 48 hrs by MTT assay, GI50=0.000432μM	28211277
KM20L2	Growth inhibition assay		48 hrs	Growth inhibition of human KM20L2 cells incubated for 48 hrs by MTT assay, GI50=0.000599μM	28211277
NCI-H460	Growth inhibition assay		48 hrs	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by MTT assay, GI50=0.000683μM	28211277
HCT116	Function assay	0.5 mM	24 hrs	Effect on mitochondrial respiration in human HCT116 cells expressing carbonic anhydrase 9 assessed as reduction in oxygen consumption rate at 0.5 mM after 24 hrs under hypoxic condition by Western blot analysis	28895394
DU145	Growth inhibition assay		48 hrs	Growth inhibition of human DU145 cells after 48 hrs by SRB assay, GI50=0.000418μM	28895394
SF268	Growth inhibition assay		48 hrs	Growth inhibition of human SF268 cells after 48 hrs by SRB assay, GI50=0.000432μM	28895394
KM20L2	Growth inhibition assay		48 hrs	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay, GI50=0.000599μM	28895394
NCI-H460	Growth inhibition assay		48 hrs	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay, GI50=0.000683μM	28895394
MCF7	Growth inhibition assay		48 hrs	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay, GI50=0.000404μM	28926240
DU145	Growth inhibition assay		48 hrs	Growth inhibition of human DU145 cells after 48 hrs by SRB assay, GI50=0.000418μM	28926240
SF268	Growth inhibition assay		48 hrs	Growth inhibition of human SF268 cells after 48 hrs by SRB assay, GI50=0.000432μM	28926240
KM20L2	Growth inhibition assay		48 hrs	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay, GI50=0.000599μM	28926240
NCI-H460	Growth inhibition assay		48 hrs	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay, GI50=0.000683μM	28926240
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	28972755
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay, EC50=0.0005μM	28972755
SKOV3	Cytotoxicity assay		2 days	Cytotoxicity against human SKOV3 cells after 2 days by cell titer 96 aqueous one solution based assay, IC50=0.00066μM	29454703
A549	Cytotoxicity assay		2 days	Cytotoxicity against human A549 cells after 2 days by cell titer 96 aqueous one solution based assay, IC50=0.0013μM	29454703
L1210	Cytotoxicity assay		2 days	Cytotoxicity against mouse L1210 cells after 2 days by cell titer 96 aqueous one solution based assay, IC50=0.0021μM	29454703
NCI-H524	Cytotoxicity assay		2 hrs	Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay, IC50=0.0037μM	30735385
Clicca per visualizzare più dati sperimentali sulle linee cellulari

Informazioni chimiche, conservazione e stabilità (Chemical Information, Storage & Stability)

Peso molecolare	717.98	Formula	C₃₉H₆₇N₅O₇	Conservazione (Dalla data di ricezione)	3 anni-20°Cpolvere
N. CAS	474645-27-7	Scarica SDF		Conservazione delle soluzioni stock	1 anno-80°Cin solvente 1 mese-20°Cin solvente
Sinonimi	SGD-1010			Smiles	CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC

Solubilità (Solubility)

In vitro
Lotto:

DMSO : 100 mg/mL (139.27 mM)
(Il DMSO contaminato da umidità può ridurre la solubilità. Utilizzare DMSO fresco e anidro.)

Ethanol : 100 mg/mL

Water : Insoluble

Calcolatore di Molarità

Massa	Concentrazione	Volume	Peso molecolare
=	×	×

Calcolatore di Diluizione Calcolatore del Peso Molecolare

In vivo Lotto:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validato dai laboratori Selleck. Se necessiti di modifiche a questa formulazione, contatta il nostro team di vendita per test personalizzati.	5.000mg/ml (6.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calcolatore di formulazione in vivo (Soluzione chiara)

Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)

Dosaggio: mg/kg Peso medio degli animali: g Volume di dosaggio per animale:μL Numero di animali:

Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Risultati del calcolo:

Concentrazione di lavoro: mg/ml;

Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH₂O, mescolare e chiarire.

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.

Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.

Meccanismo d'azione (Mechanism of Action)

In vitro	When coupled to cAC10, MMAE shows selective cytotoxicity in CD30⁺ cells, and induces G2/M-phase growth arrest and cell death through the induction of apoptosis. When coupled to anti-CD79b antibody, anti–CD79b-vcMMAE has very potent and broad activity across a large panel of NHL cell lines in vitro. When coupled to anti-HER2 antibody, hertuzumab-vc-MMAE can also be effectively internalized and potently kill HER2 over-expressing tumor cells.
In vivo	In the Karpas 299 ALCL model, cAC10-vcMMAE (1 mg/kg, i.v.) induces complete, durable tumor regression, while free MMAE (0.36 mg/kg) doesn’t produce detectable antitumor activity. In mouse xenograft models of NHL, anti–CD79b-vcMMAE (7 mg/kg, p.o.) strikingly results in sustained complete tumor remission.
Riferimenti	[1] https://pubmed.ncbi.nlm.nih.gov/12714494/ [2] https://pubmed.ncbi.nlm.nih.gov/19633198/ [3] https://pubmed.ncbi.nlm.nih.gov/26253944/ [4] https://pubmed.ncbi.nlm.nih.gov/28923397/

Informazioni sullo studio clinico (Clinical Trial Information)

(dati da https://clinicaltrials.gov, aggiornato il 2024-05-22)

Numero NCT	Reclutamento	Condizioni	Sponsor/Collaboratori	Data di inizio	Fasi
NCT06395103	Not yet recruiting	B-cell Acute Lymphoblastic Leukemia\|Diffuse Large B-cell Lymphoma\|Burkitt Lymphoma\|Neuroblastoma\|Ewing Sarcoma	Merck Sharp & Dohme LLC	June 4 2024	Phase 1\|Phase 2
NCT06227156	Recruiting	Castration-resistant Prostate Cancer	RemeGen Co. Ltd.	April 8 2024	Phase 1
NCT06265727	Recruiting	Solid Tumor Adult	Corbus Pharmaceuticals Inc.\|CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.	April 1 2024	Phase 1\|Phase 2
NCT06351020	Not yet recruiting	Locally Advanced or Metastatic GC and GCJ Adenocarcinoma	LaNova Medicines Zhejiang Co. Ltd.\|LaNova Medicines Limited	April 1 2024	Phase 3

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

MMAE (Monomethyl auristatin E) Agente Antineoplastico

Peso molecolare: 717.98

Controllo Qualità (Quality Control)

Coltura cellulare, trattamento e concentrazione di lavoro
(Cell Culture, Treatment & Working Concentration)

Informazioni chimiche, conservazione e stabilità (Chemical Information, Storage & Stability)

Solubilità (Solubility)

Calcolatore di Molarità

Calcolatore di formulazione in vivo (Soluzione chiara)

Meccanismo d'azione (Mechanism of Action)

Informazioni sullo studio clinico (Clinical Trial Information)

MMAE (Monomethyl auristatin E) Agente Antineoplastico

Peso molecolare: 717.98

Controllo Qualità (Quality Control)

Coltura cellulare, trattamento e concentrazione di lavoro (Cell Culture, Treatment & Working Concentration)

Informazioni chimiche, conservazione e stabilità (Chemical Information, Storage & Stability)

Solubilità (Solubility)

Calcolatore di Molarità

Calcolatore di formulazione in vivo (Soluzione chiara)

Meccanismo d'azione (Mechanism of Action)

Informazioni sullo studio clinico (Clinical Trial Information)

Coltura cellulare, trattamento e concentrazione di lavoro
(Cell Culture, Treatment & Working Concentration)